Applications of Nanobodies in Biological Imaging
Cancer Biotherapy and Radiopharmaceuticals · 2025
DOI: 10.1089/cbr.2025.0005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Biotherapy and Radiopharmaceuticals, 2025. Verfasst von Liangjü Sheng und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Jiangsu University, Zhenjiang, China. Hauptthemen laut MEDLINE: Single-Domain Antibodies, Molecular Imaging, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 74 Literaturangaben.
Abstract (Originalsprache)
Background
Nanobodies (Nbs), derived from Camelidae heavy-chain antibodies, are single-domain fragments (15 kDa) with high antigen-binding specificity, enhanced tissue penetration, and low immunogenicity. These attributes address limitations of conventional antibodies, positioning Nbs as pivotal tools for targeted molecular imaging in diagnostics and therapeutics.
Methods
Nbs are screened through phage/mRNA display or single B-cell sequencing, expressed in prokaryotic or yeast systems, and humanized via CDR grafting. Functional probes are engineered by conjugating Nbs with radionuclides (68Ga, 99mTc) or fluorophores (IRDye 800CW) for compatibility with PET, SPECT, NIRF, and ultrasound modalities.
Results
Clinical trials validated Nb efficacy: 68Ga-HER2-Nb PET/CT achieved tumor-specific uptake in HER2+ cancers (NCT04467515), while 99mTc-PD-L1-Nb enabled quantitative SPECT-guided immunotherapy in NSCLC. NIRF-Nb conjugates (e.g., 11A4-800CW) enhanced intraoperative tumor delineation in murine models. Dual-targeted ultrasound microbubbles demonstrated multi-biomarker imaging via acoustic pressure modulation.
Conclusion
Nbs advance biological imaging through superior resolution and rapid pharmacokinetics. Challenges persist in optimizing probe stability, minimizing immunogenicity, and scaling production. Future priorities include integrating multi-modal platforms, expanding applications to neurodegenerative disorders, and refining personalized diagnostic paradigms, underscoring their transformative potential in precision medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Jiangsu University, Zhenjiang, China.
- School of Life Sciences, Jiangsu University, Zhenjiang, China.
ORCID-Profile: Peng Lü
Zitieren
APA
Sheng, L., Sheng, K., & Lü, P. (2025). Applications of Nanobodies in Biological Imaging. Cancer Biotherapy and Radiopharmaceuticals. https://doi.org/10.1089/cbr.2025.0005
Vancouver
Sheng L, Sheng K, Lü P. Applications of Nanobodies in Biological Imaging. Cancer Biotherapy and Radiopharmaceuticals. 2025. doi:10.1089/cbr.2025.0005
BibTeX
@article{Sheng2025,
author = {Sheng, Liangjü and Sheng, Kai and Lü, Peng},
title = {Applications of Nanobodies in Biological Imaging},
journal = {Cancer Biotherapy and Radiopharmaceuticals},
year = {2025},
doi = {10.1089/cbr.2025.0005}
}
EUVIMED